Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Salek-Ardakani Shahram — Janux Therapeutics, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Salek-Ardakani Shahram

Salek-Ardakani Shahram

Chief Scientific Officer at Janux Therapeutics, Inc. · on record since Jul 20, 2021

Insider trading activity of Salek-Ardakani Shahram

Transactions on record: 1; since Jan 5, 2022

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Jan 5, 2022

Figures computed from official regulatory filings — methodology.

Companies where Salek-Ardakani Shahram has traded

Janux Therapeutics, Inc.1 tx · Jan 5, 2022

Track record of Salek-Ardakani Shahram

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Salek-Ardakani Shahram

Co-insiders of Salek-Ardakani Shahram

Avalon BioVentures I, LPJanux Therapeutics, Inc.
Avalon BioVentures SPV I, L.P.Janux Therapeutics, Inc.
Avalon Ventures XI, L.P.Janux Therapeutics, Inc.
Barrett Ronald WJanux Therapeutics, Inc.
Bregua CorpJanux Therapeutics, Inc.
Campbell David AlanJanux Therapeutics, Inc.
CAPPS VICKIE LJanux Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

DiRaimondo ThomasJanux Therapeutics, Inc.

Dobek MariaJanux Therapeutics, Inc.

DOBMEIER ERICJanux Therapeutics, Inc.

Doyle Janeen NoelJanux Therapeutics, Inc.

Godfrey WayneJanux Therapeutics, Inc.

Go WilliamJanux Therapeutics, Inc.

Gujrathi SheilaJanux Therapeutics, Inc.

Heller StefanJanux Therapeutics, Inc.

Hernday NatashaJanux Therapeutics, Inc.

JANEX INTERNATIONAL INCJanux Therapeutics, Inc.

Kolchinsky PeterJanux Therapeutics, Inc.

Kung WinstonJanux Therapeutics, Inc.

Lichter JayJanux Therapeutics, Inc.

McIver ZachariahJanux Therapeutics, Inc.

McNulty Alana B.Janux Therapeutics, Inc.

Meyer Andrew HollmanJanux Therapeutics, Inc.

ORBIMED ADVISORS LLCJanux Therapeutics, Inc.

OrbiMed Capital GP VIII LLCJanux Therapeutics, Inc.

OrbiMed Capital GP VII LLCJanux Therapeutics, Inc.

OrbiMed Genesis GP LLCJanux Therapeutics, Inc.

RA Capital Biotech Fund LPJanux Therapeutics, Inc.

RA CAPITAL MANAGEMENT, LLCJanux Therapeutics, Inc.

RA Capital Nexus Fund II, L.P.Janux Therapeutics, Inc.

Reardon TigheJanux Therapeutics, Inc.

Robinson ByronJanux Therapeutics, Inc.

Scott LaurenJanux Therapeutics, Inc.

Shah Rajeev M.Janux Therapeutics, Inc.

Simson JakeJanux Therapeutics, Inc.

Thompson Peter AJanux Therapeutics, Inc.

Winter Charles M.Janux Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Janux Therapeutics, Inc.	Jan 5, 2022	AwardD	114,250	0.00 USD	$0	SEC